spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Merck Introduces New Integrated Plug & Play Upstream Development Service

Merck


• Adaptive approach to cell line development, analytics and clone selection for emerging biotechs and start-up
• Tailored upstream development from a single source reduces time to clinic by 20 percent
• Fast-track process reduces timeline by 10 weeks for first pharmacodynamic experiment

July 17, 2019

Merck has launched its Plug & Play Upstream Development Service to help emerging biotech and start-up companies optimize the cost and speed of advancing their molecule to the clinical stage. Eliminating the need to work with multiple vendors for upstream development, the new service reduces bottlenecks, lowering time to clinic by two months. With 60 percent of drugs in the pipeline today being developed by emerging biotech companies, Merck’s tailored, streamlined service is poised to have a significant impact on drug development efficiency.

The Plug & Play Upstream Development Service includes:

• Cell line development, utilizing CHO cell lines or Merck’s proprietary CHOZN® license
• Standard analytics and early material from stable pools
• Stability study and clone selection

In the early stages of upstream development, cell line development and analytical development occur in parallel, allowing molecules to progress faster.

For customers looking to progress at an even faster speed, Merck offers its fast-track process by running process development and clone development steps in parallel, balancing speed and risk without sacrificing quality. The company’s robust and automated mini-pool approach allows it to more efficiently generate early material for process development, reducing the timeline by 10 weeks for the first pharmacodynamic experiment at the pre-clinical stage.

Customers are supported by a dedicated project manager and Merck expertise including risk assessment and regulatory expertise. Monoclonality and stability validation is fully documented based on regulatory expectations and a statistical approach. There are no royalty fees and customers have the freedom to technology transfer at any stage, to any partner.

Optional, add-on plug and play services are available, depending on customers’ needs, including:

• Off-the-shelf media and feed screening
• Analytical method development
• Complete analytics
• GMP master cell bank (MCB) and cell bank characterization
• MCB storage

Customers also have the option for Merck's BioReliance® Product Characterization team to synthesize data from multiple analytical and bioanalytical methods to help reveal the true identity of the product, ensuring the biotherapy’s safety, purity and potency with off-the-shelf mAb-based assay packages or a custom assay tailored for the biologic. Based on the mAbs needs, the product characterization team would recommend vital assays to provide all key physiochemical, binding and functional critical quality attributes and selects the lead clone for the generation of the desired product.

The Plug & Play Upstream Development Service demonstrates how Merck's BioReliance® End to End Solutions help companies realize their drug development goals. With more than 32 years of experience and over 250 biomolecules, this group helps small-sized biotech companies and start-ups at all stages from molecule development towards commercialization—in any geography— to address key challenges.
phone +33 (0)5 57 960 960
email Sebastien.ribault@merckgroup.com
web www.merckmillipore.com/adaptive-CDMO
email 1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Turkish Cargo includes Sheremetyevo Airport near Moscow to its cargo flights network.

As the fastest growing brand among the global air cargo carriers with its extensive flights network, Turkish Cargo included Sheremetyevo Airport (SVO), known as being the most important airport in Russia in terms of cargo activities, to its direct cargo flight destinations network.
More info >>


White Papers

How to Reduce Costs of Specialty Pharmaceutical Shipments and Increase Patient Satisfaction

Temptime Corporation

The specialty pharmacy industry could reduce costs by $27.5 million annually (product and call center staff costs only) if visual temperature indicators were used as decision-making tools to determine if medicine should be used or returned when patients suspect heat damage. In addition, 97% of patients surveyed, who received medicine from specialty pharmacies with a visual temperature indicator included in the package, agree that they would want an indicator in all shipments and 95% agree the indicator increased their confidence in the medicines received.
More info >>

Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement